1 week Ago By Defense World Staff
Bank of Montreal Can reduced its stake in shares of Novavax, Inc. (NASDAQ:NVAX – Free Report) by 99.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The firm owned 14,315 shares of the biopharmaceutical company’s stock after selling 2,440,010 shares during the quarter. Bank of Montreal Can’s holdings in Novavax were worth $115,000 at the end of the most recent quarter. Several other institutional investors also recently added to or reduced their stakes in NVAX.
Vanguard Group Inc. grew its stake in Novavax by 1.9% in the 4th quarter.
Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company’s stock worth $126,439,000 after acquiring an additional 296,181 shares in the last quarter. Shah Capital Management grew its stake in Novavax by 13.
6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company’s stock worth $89,637,000 after purchasing an additional 1,333,305 shares in the last quarter. Geode Capital Management LLC increased its holdings in Novavax by 4.
4% during the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company’s stock worth $29,415,000 after purchasing an additional 155,206 shares during the period. Charles Schwab Investment Management Inc.
raised its position in Novavax by 3.0% during the 4th quarter. Charles Schwab Investment Management Inc.
now owns 1,365,414 shares of the biopharmaceutical company’s stock valued at $10,978,000 after purchasing an additional 39,906 shares in the last quarter. Finally, TSP Capital Management Group LLC lifted its holdings in shares of Novavax by 0.6% in the 4th quarter.
TSP Capital Management Group LLC now owns 1,358,565 shares of the biopharmaceutical company’s stock worth $10,923,000 after buying an additional 7,700 shares during the period. Hedge funds and other institutional investors own 53.04% of the company’s stock.
Novavax Stock Down 5.7 %NASDAQ NVAX opened at $6.67 on Friday.
Novavax, Inc. has a 52 week low of $4.10 and a 52 week high of $23.
86. The company has a 50 day moving average price of $7.13 and a 200 day moving average price of $8.
35. The firm has a market cap of $1.07 billion, a PE ratio of -2.
95, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15.
Novavax (NASDAQ:NVAX – Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.
75) by $0.24. The business had revenue of $88.
31 million for the quarter, compared to analyst estimates of $85.48 million. During the same period in the previous year, the company posted ($1.
44) earnings per share. On average, equities research analysts anticipate that Novavax, Inc. will post -1.
46 earnings per share for the current fiscal year. Wall Street Analysts Forecast GrowthNVAX has been the subject of several recent research reports. BTIG Research began coverage on Novavax in a report on Friday, February 28th.
They issued a “buy” rating and a $19.00 price objective for the company. TD Cowen raised shares of Novavax to a “hold” rating in a report on Thursday, February 27th.
One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Novavax presently has a consensus rating of “Hold” and a consensus target price of $18.00.
Get Our Latest Analysis on NVAXAbout Novavax (Free Report)Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.Read MoreFive stocks we like better than NovavaxStock Market Sectors: What Are They and How Many Are There? Markets Think Robinhood Earnings Could Send the Stock UpBasic Materials Stocks InvestingChurchill Downs Stock: Could Tariff Fears Dampen Derby Gains?How to invest in marijuana stocks in 7 steps AT&T: Subscriber Growth & Buybacks Signal Bullish TurnaroundWant to see what other hedge funds are holding NVAX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Novavax, Inc. (NASDAQ:NVAX – Free Report)..
